Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Advanced Liposarcoma or Leiomyosarcoma: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Advanced Liposarcoma or Leiomyosarcoma: 1 US clinical trial tracked, none currently recruiting.

Advanced Liposarcoma or Leiomyosarcoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 1 of these trials.

Enrollment posture brief

Registry condition advanced-liposarcoma-or-leiomyosarcoma

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Advanced Liposarcoma or (this)Advanced Liposarcoma or (th…0%
Open-enrollment share among volume-matched conditions near Advanced Liposarcoma or Leiomyosarcoma

Advanced Liposarcoma or Leiomyosarcoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Liposarcoma or Leiomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Liposarcoma or Leiomyosarcoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Advanced Liposarcoma or Leiomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Trabectedin Drug
1 trials
Dacarbazine Drug
1 trials

US sites by state

Facility locations filed on Advanced Liposarcoma or Leiomyosarcoma trials. A trial with sites in several states counts in each.

Georgia 1 trials
Florida 1 trials
Connecticut 1 trials
Colorado 1 trials
California 1 trials
Arizona 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Liposarcoma or Leiomyosarcoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Advanced Liposarcoma or Leiomyosarcoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Janssen Research & Development sponsors the most Advanced Liposarcoma or Leiomyosarcoma trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Liposarcoma or Leiomyosarcoma condition card totals 1 registered trials; most-linked intervention Trabectedin; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.